Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1775 and Olaparib in Refractory Solid Tumours
NCT02511795Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2015
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of adavosertib in solid tumor and small cell lung cancer (SCLC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Incidence of Dose-Limiting Toxicities at 21 days and Treatment-Emergent Adverse Events at 12 months. Started Aug 2015; status: completed.
02
Drugs
adavosertib
03
Conditions
solid tumorsmall cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02511795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02511795.